Jump to content

Latanoprostene bunod

From Wikipedia, the free encyclopedia
(Redirected from Vyzulta)

Latanoprostene bunod
Clinical data
Trade namesVyzulta
Other namesBOL-303259-X
AHFS/Drugs.comMonograph
License data
Drug classProstaglandin analog
ATC code
Legal status
Legal status
Identifiers
  • 4-Nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.251.571 Edit this at Wikidata
Chemical and physical data
FormulaC27H41NO8
Molar mass507.624 g·mol−1
3D model (JSmol)
  • C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O
  • InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
  • Key:LOVMMUBRQUFEAH-UIEAZXIASA-N

Latanoprostene bunod, sold under the brand name Vyzulta, is an ophthalmic medication used for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2][3] It targets the trabecular meshwork directly.[3] It is a prostaglandin analog.[2]

The most common side effects include conjunctival (eye) redness, eye irritation, and eye discomfort (pain).[4] Latanoprostene bunod may cause the iris (colored part of the eye) to become darker in color.[4]

Latanoprostene bunod was approved for medical use in the United States in November 2017.[2][4][5]

Medical uses

[edit]

Latanoprostene bunod is indicated for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2]

History

[edit]

The US Food and Drug Administration (FDA) approved latanoprostene bunod based on evidence from two clinical trials that enrolled 840 participants with open angle glaucoma or ocular hypertension.[4] The trials evaluated the benefits and side effects of latanoprostene bunod.[4] In each trial, participants were randomly assigned to receive either latanoprostene bunod or an approved drug timolol (ophthalmic solution) every day for three months.[4] Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed.[4] The trials were conducted in the United States, the United Kingdom, Germany, Italy, Bulgaria, the Czech Republic, and Japan.[4]

References

[edit]
  1. ^ "Regulatory Decision Summary for Vyzulta". Health Canada. 27 December 2018.
  2. ^ a b c d e "Vyzulta- latanoprostene bunod solution/ drops". DailyMed. 1 May 2019. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
  3. ^ a b Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.
  4. ^ a b c d e f g h "Vyzulta". U.S. Food and Drug Administration (FDA). 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ "Bausch + Lomb And Nicox Announce FDA Approval Of Vyzulta (Latanoprostene Bunod Ophthalmic Solution), 0.024%" (Press release). Valeant Pharmaceuticals. 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024 – via PR Newswire.